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Abstract
Background: Venous thromboembolism (VTE, including deep vein thrombosis [DVT] and pulmonary embolism [PE])
has an annual incidence rate of 104–183 per 100,000 person-years. After a VTE episode, the two-year recurrence rate is
about 17%. Consequently, effective and safe anticoagulation is paramount. Edoxaban is a direct oral anticoagulant
(DOAC) approved VTE treatment. Current safety and efficacy data are derived from clinical trials, and information about
treatment durations beyond 12 months are not available.
Methods: ETNA-VTE-Europe is an 18-month prospective, single-arm, non-interventional, multinational post-authorisation
safety study. Approximately 310 sites across eight European countries (Austria, Belgium, Germany, Ireland, Italy, the
Netherlands, Switzerland and the United Kingdom) will participate in the study, with the intention to represent the
regional distributions of centres, healthcare settings and specialties. An estimated cohort of 2700 patients will be
recruited, the only enrolment criteria being acute symptomatic VTE, no participation in an interventional study, and
treating physician decision to prescribe edoxaban independently from the registry. Data from patient medical records
and/or telephone interviews will be collected at baseline, 1, 3, 6, 12 and 18 months. The primary objective is to evaluate
the 18-month rate of symptomatic VTE recurrence in patients with VTE treated with edoxaban outside a clinical trial. The
co-primary objective is to evaluate the real-world rates of bleeding and adverse drug reactions. Secondary outcomes
include rates of other patient-relevant safety events, adherence to and discontinuation of edoxaban. Furthermore, 12-
month ETNA-VTE-Europe data will be considered in the context of those for patients receiving different anticoagulants in
the PREFER in VTE registry and Hokusai-VTE clinical trial.
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Conclusions: ETNA-VTE-Europe will allow the safety and effectiveness of edoxaban to be evaluated over an extended
period in acute symptomatic VTE patients encountered in routine clinical practice. Findings will be informative for
European practitioners prescribing edoxaban as part of real-world VTE treatment/prevention.
Trial registration: ClinicalTrials.gov Identifier: NCT02943993.
Keywords: Venous thromboembolism (VTE), Edoxaban, Direct oral anticoagulant (DOAC/NOAC), Anticoagulation, Registry
Background
Venous thromboembolism (VTE), which encompasses
both deep-vein thrombosis (DVT) and pulmonary
embolism (PE), has an annual incidence rate of approxi-
mately 104–183 per 100,000 person-years in individuals
of European descent [1]. VTE is the third most common
cardiovascular disease. The case-fatality rate is higher
after PE than after DVT [2, 3]. Nevertheless, both events
increase the probability of subsequent recurrent VTE,
which affects approximately 17% of patients at 2 years,
indicating that VTE is a chronic disease [4]. Conse-
quently, effective anticoagulation to treat first-time VTE
and prevent its recurrence is paramount.
Edoxaban is a direct oral anticoagulant (DOAC),
which exerts its effects through inhibition of factor Xa.
Based on results from the ENGAGE AF-TIMI 48 and
Hokusai-VTE trials [5, 6], it was approved by the Euro-
pean Medicines Agency (EMA) regulatory for two main
indications: the prevention of stroke/systemic embolism
in patients with non-valvular atrial fibrillation (NVAF)
with one or more risk factor, and the treatment/second-
ary prevention of acute VTE (DVT and/or PE) in adults
[7]. However, current evidence for the safety and efficacy
of edoxaban is derived from the patient populations en-
rolled in clinical trials. Furthermore, though current
guidelines recommend that anticoagulation following
VTE should be continued for at least 3 months and up
to an indefinite duration, depending upon the risk of
recurrence [8], no data currently exist for treatment with
edoxaban beyond 12 months.
As part of an ongoing European risk-management
plan, several post-authorisation safety studies (PASS)
have been designed to assess the real-world outcomes of
edoxaban-treated patients in the EMA-approved indica-
tions [9]. Here we describe the design and rationale for
the “Edoxaban Treatment in routine cliNical prActice
for patients with acute Venous ThromboEmbolism in
Europe” (ETNA-VTE-Europe) PASS, the protocol for
which has been reviewed and approved by the EMA’s
Pharmacovigilance Risk Assessment Committee (PRAC),
in accordance with new regulatory requirements. The
aim of this PASS is to gain further insight into the safety
and effectiveness of treatment and secondary prevention
of VTE with edoxaban up to 18 months in routine
clinical practice. This study forms part of a global
program and safety data will eventually be pooled with
ETNA-AF-Europe data and with those from similar
Japanese, Thai, Chinese, Taiwanese and Korean regional
registries to assess the safety outcomes associated with
edoxaban on a worldwide scale.
Methods
ETNA-VTE-Europe is a single-arm, multinational, pro-
spective, non-interventional PASS, which will be con-
ducted across approximately 310 sites in 8 European
countries (Austria, Belgium, Germany, Ireland, Italy, the
Netherlands, Switzerland and the United Kingdom). The
registry will enrol approximately 2700 patients with
acute VTE treated with edoxaban, who will be followed
over the 18 months subsequent to the index VTE.
Approval from the responsible ethics committees and in-
stitutional review boards will be obtained prior to proto-
col implementation. Informed consent will be obtained
from all patients prior to enrolment and compliance
with the Declaration of Helsinki will be ensured
throughout the study.
Objectives and outcome measures
The primary objective of ETNA-VTE-Europe is to
quantify the long-term rate of VTE recurrence in a large,
real-world population of acute symptomatic VTE pa-
tients prescribed edoxaban as part of their initial treat-
ment regimen. Accordingly, the primary outcome
measure will be the proportion of such patients who
experience recurrent symptomatic VTE on one or more
occasions within the 18 months following their index
VTE, regardless of the length of edoxaban exposure.
The co-primary objective is to collect and evaluate
real-world safety data regarding adverse drug reactions
(ADRs) in patients treated with edoxaban across the
currently approved indications. Therefore, ETNA-VTE-
Europe data will be combined with 18-month safety data
from the Edoxaban Treatment in routine cliNical PrAc-
tice for patients with non-valvular Atrial Fibrillation in
Europe (ETNA-AF-Europe) study, a parallel European
PASS evaluating the safety and effectiveness of edoxaban
in real-world treatment of atrial fibrillation (AF) [10].
The outcome measure will be the proportion of patients
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who experience death (all-cause, cardiovascular, and VTE-
related), bleeding events (major, clinically relevant non-
major [CRNM], and minor bleeding; defined according to
International Society on Thrombosis and Haemostasis
[ISTH] criteria [11]), hepatic events, and/or other ADRs
before the 18 month time-point in the two studies.
Secondary objectives are as follows: to evaluate the
effects of persistent edoxaban use and permanent dis-
continuation on the rate of recurrent symptomatic VTE;
to assess the rates of patient-relevant safety outcomes,
including bleeding, ischaemic/haemorrhagic stroke, sys-
temic embolic events (SEE), post-thrombotic syndrome
(PTS), death, and hospitalisation due to cardiovascular
causes; and to characterise the extent of adherence to
edoxaban, reasons for and rate of discontinuation. To
evaluate the effectiveness and safety of edoxaban relative
to other anticoagulants, primary and secondary ETNA-
VTE outcome data will be appraised in the context of
those from the PREFER in VTE real-world registry and
Hokusai-VTE clinical trial [12, 13]. The influence of
study setting will also be explored by considering real-
world ETNA-VTE data in the context of edoxaban data
from the Hokusai-VTE clinical trial [12].
Site selection
In order to represent the regional distributions of
centres, healthcare settings, specialties, and approaches
to VTE treatment, a sequential site selection process is
underway. This involves identification of potential sites,
acquisition of relevant institutional details via a feasibil-
ity questionnaire, assessment of suitability, and invitation
to participate. To be considered eligible, sites are re-
quired to have access to acute VTE patients expected to
receive edoxaban treatment, the ability to access the
Electronic Data Capture (EDC) system and record data
in English, and adequate time and staff to perform all
study-related documentation activities. They must also
agree to complete a screening log with the aim of maxi-
mising the potential for consecutive enrolment, and to
perform follow-ups according to routine clinical practice.
There is an upper limit of 100 patients per site.
Patient recruitment
The original version of the ETNA-VTE-Europe protocol
was approved by the Swiss Agency for Therapeutic
Products (Swissmedic) and the central Ethics Committee
in Switzerland in February 2015. Accordingly, Swiss sites
began enrolling patients at this time. However, protocol
revision was necessary due to a change in EMA legisla-
tion and a revised PRAC process in July 2015. Upon the
approval of the new protocol by the EMA’s PRAC in
September 2016, Swiss regulatory bodies were informed
of the changes and new approval sought. Patient recruit-
ment according to the revised protocol is now underway,
taking place in two waves; the first extends from the last
quarter of 2016 to the second quarter of 2018
(Switzerland and Germany) and the second from the
first quarter of 2017 to the last quarter of 2018 (all other
countries). In each country, the recruitment period will
last 2 years, with the aim of obtaining a representative
study population of approximately 2700 VTE patients
from a variety of healthcare settings.
To be included in the study, patients must have been
diagnosed with initial or recurrent acute VTE (distal or
proximal DVT and/or PE) that occurred no more than 2
weeks prior to enrolment. In addition, the treating phys-
ician must have decided to prescribe the patient edoxa-
ban, with indications that are in line with the edoxaban
Summary of Product Characteristics (SmPC). All treat-
ment decisions are independent of the registry and
completely at the discretion of the treating physician
and/or patient, with no reimbursement for any drugs or
therapy received during the study. As such, any con-
comitant treatment is allowed and changes to medica-
tion are unrestricted. The only exclusion criteria are lack
of written informed consent and participation in a
simultaneous interventional study.
Documentation and assessment
Data for this study will be sourced from medical records
and, when in line with routine clinical practice, from
telephone calls between the patient and treating phys-
ician. As a non-interventional study, no patient contact,
examinations, laboratory tests or procedures are com-
pulsory, and will only be carried out at the discretion of
the treating physician, as and when deemed appropriate
and without registry influence. A standardised electronic
case report form (eCRF) will be completed by the site
shortly after enrolment and again after every interaction
with a patient over the subsequent 18 months. The
eCRFs will be uploaded to the secure, internet-based
Medidata Rave EDC system.
Given that the edoxaban SmPC recommends 5 days of
parenteral anticoagulation following VTE before starting
edoxaban treatment [7], baseline is defined as the first
day of heparin/fondaparinux administration after the
index acute VTE event. The first data entry, which will
be completed following enrolment and within 2 weeks
of the index VTE, will include details of baseline patient
characteristics, comorbidities, VTE-related parameters,
past and current therapy, and other relevant assessments
made according to site protocol (Table 1). Memory aids
will be provided to all patients at enrolment, with space
to record edoxaban-related treatment changes, use of
concomitant medication, adverse events, hospitalisation,
physician contact, and productivity loss. This aid can be
used to assist with recall during subsequent visits/tele-
phone calls, but are voluntary and will not be formally
Cohen et al. Thrombosis Journal  (2018) 16:9 Page 3 of 13
assessed. In each country, all patients will be followed
until the last patient for that particular country has com-
pleted the 18-month documentation period, in line with
EMA requirements. At this point, a last-patient-out
(LPO) questionnaire, requesting a minimum of vital sta-
tus, will be issued for each patient enrolled in the re-
spective country.
Upon completion of the ETNA-VTE-Europe registry,
data will be extracted for the following time points:
baseline, 1, 3, 6, 12 and 18 months. Details of the param-
eters to be evaluated at each time point are outlined in
Table 1. The current status, change/events since baseline
and change/events since the previous time point will be
assessed for each parameter, as appropriate. In addition,
recurrence of symptomatic VTE and death since the 18-
month time point will be retrospectively documented at
the time of LPO per country.
Definitions
All variables in the ETNA-VTE-Europe study are defined
as similarly as possible to those in the PREFER in VTE
and Hokusai-VTE studies to permit close comparison of
results [6, 13–15]. However, the feasibility of this is some-
what limited by the non-interventional setting. A com-
parison of the most important variable definitions is
provided in Table 2. Permanent edoxaban discontinuation
is defined as cessation of edoxaban treatment within the
follow-up period.
Quality control
ETNA-VTE-Europe will be conducted in accordance
with the Guidelines for Good Pharmacoepidemiology
Practice (GPP) and the EMA Guideline on Good Phar-
macovigilance Practices (GVP) Module VIII (manage-
ment and reporting of adverse reactions to medicinal
products; EMA/813938/2011 rev 1) [16, 17]. Automated
checks for plausibility and integrity will be carried out at
data entry to permit correction or confirmation by the
site. Furthermore, approximately 30% of sites will be
randomly selected to undergo on-site monitoring, during
which random source data verification will be per-
formed. In particular, monitoring activities will closely
assess the completeness and correctness of safety data.
Patients with missing observations for a particular time
point and/or parameter will be omitted from the corre-
sponding analyses.
Sample size calculations
Assuming an overall 18-month symptomatic VTE recur-
rence rate [12, 13] of 8.0% in patients who receive
Table 1 Time points for data assessment
Baseline* 1 month 3 months 6 months 12 months 18 months Country-specific LPO
Eligibility criteria(1) X
Baseline characteristics(2) X
VTE-related parameters(3) X X§ X§ X§ X§ X§
Edoxaban therapy(4) X X X X X X
Concomitant anticoagulants X X X X X X
Interventions X X X X X X
Adherence to VTE therapy(5) X X X X X X
Recurrent VTE(6) X X X X X X†
Other clinical events(7) X X X X X X
Hospitalisation for cardiovascular disease(8) X X X X X
PTS(9) X X X X
Vital signs(10) X X X X X X
Laboratory parameters(9) X X X X X X
ADRs(11) X X X X X X
Legend: VTE, venous thromboembolism; PTS, post-thrombotic syndrome; ADR, adverse drug reaction; LPO, last patient out. (1) Confirmed first or recurrent VTE
within the 2 weeks preceding enrolment; treated with edoxaban according to Summary of Product Characteristics; written informed consent; no simultaneous
interventional study participation. (2) Age and gender, alcohol consumption, smoking status, frailty, comorbidities, and medical history. (3) Details of past and
current VTE risk factors, symptoms, diagnosis, interventions, treatment, and related clinical events (stroke, bleeding events, systemic embolism, non-valvular atrial
fibrillation, and malignancies). (4) History and current status, including dose, prescription intervals, and any changes to edoxaban treatment since last data point
(including permanent discontinuation, in which case date, reason and subsequent therapy must be provided). (5) Physician judgment only. (6) Timing, diagnosis
and interventions. (7)I.e. death, stroke, bleeding events, systemic embolism, non-valvular atrial fibrillation, and malignancies. (8) Admittance and discharge dates,
clinical event, and use of the emergency room and/or intensive care unit. (9) If assessed. (10) Including blood pressure, heart rate, height and weight. (11) As per the
Guideline on Good Pharmacovigilance Practices (GVP) Module VI (Management and reporting of adverse reactions to medicinal products; EMA/873138/2011 Rev.
1) [16]; coding according to the standardised Medical Dictionary for Regulatory Activities (MedDRA).*Defined as the first day of heparin administration after the
index acute VTE event. †Since 18-month time point. §Changes in symptoms/diagnosis and any other VTE-relevant information
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edoxaban (regardless of treatment discontinuation) and
a relative precision of 15% for a two-sided 95% confi-
dence interval (95% CI), data for 1964 patients will be
required to assess with sufficient accuracy the primary
outcome. Given an expected dropout rate of 25%, enrol-
ment of 2700 patients should result in an adequate sam-
ple size for evaluation at 18 months.
In order to obtain a dataset as large as possible for
co-primary outcome assessment, safety data from
ETNA-VTE-Europe will be combined with 18-month
safety data from ETNA-AF-Europe, a sister European
PASS study of edoxaban in approximately 13,100 pa-
tients with NVAF [10]. Together, these studies will enrol
approximately 15,800 patients, with an overall expected
18-month dropout rate of 20%. Consequently, data for
approximately 12,640 patients should be available at
18 months to assess the incidence rates of interest and
their 95% CIs. A key aim of this combined analysis is to
provide sufficient statistical power to capture uncom-
mon ADRs with low incidence rates; for those that occur
at rates of 0.1–1.0%, the corresponding precision of 95%
CIs will range from ±0.06% to 0.17%.
Statistical analysis
Owing to the non-interventional study design, all
ETNA-VTE-Europe data analysis will be explorative and
descriptive only. In addition to the Europe-wide analysis,
safety and effectiveness data will be presented for each
individual country and region (Austria, Switzerland and
Germany [DACH]; the United Kingdom and Ireland
[UK/IE]; Belgium and the Netherlands [BE/NL]; and
Italy). Comparisons between patients in particular edox-
aban exposure categories (current use, recent use [within
the last 3 days], and past use [> 3 days ago], as well as
use within the last 30 days) will also be performed, with
outcome data additionally presented for all patients per-
manently discontinuing edoxaban. Furthermore, sub-
group analyses comparing patients with/without the
following baseline characteristics are planned: renal im-
pairment, hepatic impairment, DVT only (vs. PE with/
without DVT), age ≥ 75 years, male gender, initial 30 mg
edoxaban dose (vs. 60 mg), and active cancer.
To provide context to our results, the outcomes of
ETNA-VTE patients will be appraised relative to those
of PREFER in VTE patients treated with a DOAC, PRE-
FER in VTE patients treated with a vitamin-K antagonist
(VKA), Hokusai-VTE patients treated with edoxaban,
and Hokusai-VTE patients treated with warfarin. These
evaluations will be performed on an entirely visual basis,
with no joint statistical models planned. Given the one-
year follow up of the PREFER in VTE and Hokusai-VTE
studies, only 12-month data from ETNA-VTE-Europe
will be considered for these purposes [12, 13].
Data will be analysed and presented using descriptive
statistics. Categorical variables will be reported as abso-
lute numbers and percentages, and continuous variables
will be presented as means with standard deviations or
medians with interquartile ranges and minimum/max-
imum values, alongside the number of missing and non-
missing observations. For select variables, 95% CIs will
be provided. Where applicable, Kaplan-Meier analysis
will be performed to illustrate risk over time. Time-to-
event variables will be analysed using Cox proportional
hazard regression and presented as hazard ratios with
95% CIs and p-values. The type of VTE (DVT only vs.
PE ± DVT) will be included in all Cox models as an add-
itional covariate. Based on the results of the Hokusai-
VTE and the PREFER in VTE studies [6, 13], no further
confounders will be considered at this stage, but any
other relevant differences at baseline will be retrospect-
ively added to the model.
A separate analysis combining 18-month safety data from
ETNA-VTE-Europe and ETNA-AF-Europe will address
the co-primary objective. Data will be presented as absolute
and relative frequencies with 95% CIs, overall and for each
aforementioned exposure category and subgroup. All statis-
tical analyses will be performed using SAS® version 9.3 or
higher (SAS Institute, Cary, NC, USA).
Discussion
The real-world management of acute VTE has been
studied by a number of registries on a national (MAS-
TER and SWIVTER II [18, 19]), European (PREFER in
VTE [13]) and global (RIETE, GARFIELD-VTE, RE-
COVERY and XALIA [20–23]) scale. Such registries are
important because they include patients who are usually
omitted from clinical trials due to strict inclusion and
exclusion criteria, allowing appraisal of treatment re-
gimes in patients with particular characteristics. Further-
more, large-scale, non-interventional studies permit real-
world comparisons across a range of healthcare settings
and geographical locations, which may be helpful for
evaluating the relative efficiency of national healthcare
services and identifying potential improvement strat-
egies. In this sense, ETNA-VTE Europe is similar to
existing registries; however, it is different in that it
focuses on patients receiving edoxaban, a drug that more
recently been approved and is therefore not represented
in previous real-world studies. The EMA has reviewed
and approved its study protocol. Accordingly, the
present registry will add value by providing an as-yet-
unexplored insight into the use and associated outcomes
of this agent in clinical practice. A comparison between
the design of ETNA-VTE Europe and other large-scale
VTE-patient registries can be found in Table 3.
Current evidence for the safety and efficacy of edoxa-
ban largely emanates from the phase III Hokusai-VTE
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clinical trial [6]. A key limitation of this study was the
exclusion of patients with characteristics encountered in
routine clinical practice, such as those with isolated
distal symptomatic DVT, a creatinine clearance of <
30 mL/min, and significant liver disease. Consequently,
the effectiveness and safety in some clinical subgroups
to edoxaban remain unrepresented and uncharacterised.
Data gathered from the ETNA-VTE-Europe study with
minimal selection criteria will address this knowledge
gap, with several pertinent subgroup analyses already
planned. The gathered data will also provide a snapshot
of the types of patients being prescribed edoxaban, the
doses used, and the durations of treatment in a real-life
setting. This will permit appraisal of the appropriateness
of such therapeutic decisions as well as acting as a marker
for evaluation of subsequent trends of prescription.
An additional limitation of current studies is that data
are only available for up to 12 months of edoxaban
therapy [6]. Considering that a number of patients will
require longer-term anticoagulation in clinical practice
[8], those continuing edoxaban dosing beyond 12 months
will find themselves in uncharted waters. The 18-month
follow-up period planned for ETNA-VTE-Europe pa-
tients will provide clinicians and patients with valuable
information regarding the safety and net clinical benefit
of extended treatment. In particular, trends in rare ADRs
such as liver events and major bleeding will be of inter-
est, given their low frequency in the Hokusai-VTE trial
[6]. Combination of ETNA-VTE-Europe data with those
from the ETNA-AF-Europe sister study will provide an
even larger population from which to assess these safety
outcomes [10]. Thus, the present PASS is a responsible and
important part of the early post-marketing phase, designed
to address several of the knowledge gaps highlighted in the
EMA risk-management plan for edoxaban [9].
The single-arm design of the ETNA-VTE-Europe
study reflects its key aim of characterising the real-world
safety and effectiveness of edoxaban. However, visually
comparing our results to those from similar studies with
different anticoagulants will help to provide perspective.
To these ends, data from the recent PREFER in VTE
real-world registry will be used to contextualise data
from ETNA-VTE-Europe, selected for its comparable
bleeding definitions, coinciding data assessment time
points, and high patient numbers (3545 patients) [14].
This will allow us to gain an idea of the real-world safety
and effectiveness of edoxaban relative to agents such as
VKAs and other DOACs, not only in the overall popula-
tion, but also in specific patient subsets, such as those
with renal or hepatic impairment. Furthermore, several
of the countries and regional delineations in ETNA-
VTE-Europe (such as Italy, DACH and UK/IE) also
feature in the PREFER in VTE study, enabling various
approximate geographical comparisons [13]. A further
evaluation of ETNA-VTE-Europe real-world results in
the context of those from the Hokusai-VTE clinical trial
will provide insight into the influence of stringent
enrolment criteria and closer monitoring on edoxaban-
related outcomes. This will indicate to what extent the
encouraging findings from phase III studies can be
expected to translate into clinical practice.
Potential limitations
As a prospective, non-interventional registry that aims
to represent everyday occurrence and management of
VTE, the stringent inclusion/exclusion criteria, phys-
ician/patient blinding, and site/protocol standardisation
that typify RTCs do not apply. This introduces the possi-
bility for biases that are difficult to avoid, measure or
correct for. In particular, heterogeneous timing and
length of edoxaban exposure may prove problematic for
the interpretation of results, thought this will be taken
into consideration at data analysis. Furthermore, in such
a large-scale study, some incompleteness, insufficient de-
tail, or inaccuracy of patient data is unavoidable; how-
ever, measures such as the careful design of case report
forms and data monitoring/verification aim to minimise
such occurrences. Despite the inherent limitations asso-
ciated with observational registries, the all-inclusive
nature of ETNA-VTE Europe may be seen as an advan-
tage for obtaining a realistic snapshot of the clinical
climate, with two-wave recruitment potentially allowing
changes in treatment behaviour over time to be eluci-
dated. Finally, while the single-arm nature of the study
means that direct comparisons with other anticoagulants
will not be possible, close accordance between the de-
signs of PREFER in VTE and ETNA-VTE Europe should
permit a reasonable appraisal of outcome differences.
Conclusions
The international, observational ETNA-VTE-Europe
registry will allow the safety and effectiveness of edoxa-
ban in the general population of acute symptomatic
VTE patients to be assessed over an extended time
period. The planned series of explorative analyses will
provide essential information regarding edoxaban treat-
ment in a range of as-yet-unrepresented patient subsets,
the effect of treatment duration and discontinuation on
outcomes, and the relative costs/benefits associated with
edoxaban use compared to that of other commercially
available anticoagulants. Findings will help to elucidate
whether the good safety profile observed in the Hokusai-
VTE clinical trial can be extrapolated to the real-world
population, as well as providing a wealth of valuable
information for European practitioners prescribing or
contemplating the use of edoxaban as part of VTE treat-
ment/secondary prevention.
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Appendix
List of ETNA in VTE investigators
Austria
Cihan Ay, Allgemeines Krankenhaus Medizinische
Universität Wien, Wien; Matthias Hoke, AKH - Medizinische
Universität Wien, Wien; Marianne Brodmann, LKH -
Universitätsklinikum Graz, Graz; Rudolf Kirchmair,
Medizinische Universität Innsbruck, Innsbruck; Rainer
Mathies, Landeskrankenhaus Feldkirch, Feldkirch;
Markus Rauter, Klinikum Klagenfurt am Wörthersee,
Klagenfurt; Klemens Reinberg, Gemeinschaftspraxis
Wachau, Weißenkirchen in der Wachau; Vinzenz Stepan,
Krankenhaus der Elisabethinen Graz, Graz; Thomas
Maca, Ordination Dr. Maca, Wien; Hans Domanovits,
AKH - Medizinische Universität Wien, Vienna; Wolfgang
Salmhofer, Landeskrakenhaus - Universitaetsklinikum
Graz, Graz; Thomas Weiss, Wilhelminenspital der Stadt
Wien, Wien; Walter Klimscha, Sozialmedizinisches Zentrum
Ost - Donauspital, Vienna; Alexander Kober, Ordination,
Sankt Aegyd am Neuwalde; Franz Hinterreiter, Konventhos-
pital Barmherzige Brüder, Linz; Johann Auer, KH St. Josef
Braunau, Braunau; Armaghan Gomari-Grisar, Krankenhaus
Barmherzige Schwestern Wien, Wien; Joeg Jabkowski,
Krankenhaus der Elisabethinen Linz, Linz; Paul Pinter,
Wahlarzt Ordination, Dr. Paul Pinter, Altenmarkt an
der Triesting
Belgium
Philippe Hainaut, Cliniques Universitaires Saint-Luc,
Bruxelles; Laure Gilis, CHC - Clinique St-Jospeh, Liège;
Herman Schroe, Ziekenhuis Oost-Limburg, Genk; Jos
Vandekerkhof, Jessa Ziekenhuis - Campus Virga Jesse,
Hasselt; Pascal Vranckx, Jessa Ziekenhuis Hospital, Hasselt;
Peter Verhamme, UZ Leuven, Leuven; Mikhael Janssen, AZ
Groeninge - Kennedylaan, Kortrijk; Guy Vereecken, Ver-
eecken Guy, Halen; Luc De Munck, De Munck, Vilvoorde;
Bernard Vandooren, Algemeen Ziekenhuis West, Veurne;
Johan Duchateau, AZ Sint-Maarten, Duffel; Jan De Letter,
AZ Sint-Jan Brugge, Brugge; Muriel Lins, AZ Sint-Maarten,
Duffel; Jean-Claude Wautrecht, ULB Hopital Erasme,
Bruxelles; Marc Delforge, CHR de Huy, Huy; Philippe
Hermans, CHU Saint-Pierre, Bruxelles; Philippe Borgoens,
CHR Citadelle, Liege; Jean-Baptiste Nicolas, CHU UCL
Namur, Yvoir; Geoffrey Debonnaire, Sint-Elisabeth
Ziekenhuis, Zottegem; Marion Delcroix, UZ Leuven,
Leuven; Stéphane Vanden Bemden, bvba Medisch
Kabinet Dr. Vanden Bemden, Steenokkerzeel; Jaak
Mortelmans, Mortelmans, Jaak, Oostham; Muriel
Sprynger, CHU de Liege, Liège; Yohan Balthazar,
SPRL MG Balthazar & Ballard, Natoye; Geert Vileyn,
Huisartsenpraktijk Vileyn bvba, Blankenberge; Michel
Goetinck, Huisartsenpraktijk De Stoute, Brugge; Bart Segers,
Wichelen; Philippe De Vleeschauwer, Heilige Hart Ziekenhuis
Lier, Lier; Michel De Pauw, Universitair Ziekenhuis Gent,
Gent; Karen Wustenberghs, GZA Ziekenhuizen - Campus
Sint-Augustinus, Wilrijk; Roeland Dierickx, Huisartsen
Dierickx, Westouter
Germany
Dirk Härtel, Klinikum Lippe GmbH, Detmold; Gunter
Hergdt, Praxis Dr. med. Gunter Hergdt, Obermichelbach;
Holger Michel, Gemeinschaftspraxis Michel und Leffler,
Lutherstadt Eisleben; Annegret Otto, Gemeinschaftspraxis
Dres. med. Stenzel, Ebert & Otto, Riesa; Andreas Rieker,
Facharztpraxis Rieker Dr. med. Andreas Rieker -
Venenpraxis im “Gesundheitszentrum Südstraße”, Lauffen
am Neckar; Toralf Schwarz, INFO-MED Leipzig GmbH,
Markkleeberg; Jens Taggeselle, Kardiologische Praxis Dr.
Jens Taggeselle, Markkleeberg; Oliver Gastmann, Ilm-Kreis-
Kliniken Arnstadt-Ilmenau gGmbH, Arnstadt; Diana
Razavi, Praxis Diana Razavi, Steinau; Petra Herrmann,
Praxis Dipl.- Med. Petra Herrmann, Eisenach; Dag-
Alexander Keilhau, Medizinisches Versorgungszentrum für
Innere Medizin, Hamburg; Bernd-Thomas Kellner,
Gemeinschaftspraxis Dres. Niels Erhardt und Bernd-
Thomas Kellner, Dornburg-Camburg; Diethard Predel,
Praxis für Gefäßmedizin, Nordhausen; Rainer Rippert,
Praxis Dr. Rippert, Wiesbaden; Reinhardt Sternitzky,
Zentrum für klinische Prüfungen in der Facharztzentrum
Dresden-Neustadt GbR, Dresden; Andor Schmidt, Omdas
GmbH and Praxis Dr. med. Andor Schmidt, Offenbach;
Matthias Schulze, Asklepios Klinikum Schwalmstadt,
Schwalmstadt; Heiko Schneider, Medigra - Gemeinschaft-
spraxis Dres. Heiko Schneider & Peter Rostock, Apolda;
Franz Wolf, Praxis Dres. Wolf, Straubing; Andreas Greve,
Innere Medizin im Gesundheitszentrum, Ahrensburg;
Matthias Ulrich, Angiologie am Coppiplatz, Leipzig;
Norbert Schön, Kardiologie Mühldorf am Inn, Mühldorf;
Günter Rehling, Gemeinschaftspraxis Dres. Michael Eis und
Günter Rehling, Sand am Main; Bernhard Witzenbichler,
HELIOS Amper-Klinikum Dachau, Dachau; Bernadett
Brado, Praxis für Angiologie, Hämatologie, Innere Medizin
Dr. med. Bernadett Brado, Heidelberg-Neuenheim; Thomas
N. Abahji, Ärztehaus GerMedicum, Germering; Johannes
Brachmann, Klinikum Coburg GmbH, Coburg; Hans-
Walter Bindig, Praxis Dr. Bindig, Georgensgmünd; Siamak
Pourhassan, Gemeinschaftspraxis für Gefäßchirurgie/
Gefäßmedizin - Drs. Heim & Pourhassan, Oberhausen;
Tobias Geisler, Deutsches Herzkompetenzzentrum am
Universitätsklinikum Tübingen, Tübingen; Berthold
Amann, Franziskus-Krankenhaus Berlin, Akademisches
Lehrkrankenhaus der Charité, Berlin; Svetlana Tlechas-
Tkatsch, Praxis S. Tlechas-Tkatsch, Potsdam; Markus
Stücker, St. Maria-Hilf-Krankenhaus, Bochum-Gerthe;
Rainer Schmiedel, Praxis Dr. med. Rainer Schmiedel,
Kaiserslautern; Ernst G. Vester, Evangelisches Kranken-
haus Düsseldorf, Düsseldorf; Janna Dshabrailov, Praxis Dr.
Dshabrailov, Osnabrück; Ayham Al-Zoebi, Kardiologische
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Praxis Dr. Al-Zoebi, Wermsdorf; Sylvia Baumbach,
Gemeinschaftspraxis Dr. med. Sylvia Baumbach und Dr.
Elke Reichelt, Apolda; Wilma Grosskopf, Gemeinschaft-
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